NCT00241449

A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer

A Double-blind, Randomized, Multicentre Trial Comparing the Efficacy and Tolerability of 250mg of Faslodex (Long Acting ICI 182,780) With 20mg of Nolvadex (Tamoxifen) in Postmenopausal Women With Advanced Breast Cancer

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 51 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: Female
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Nolvadex (tamoxifen) as first-line treatment for postmenopausal women with advanced breast cancer. Patients will be treated until disease progression or until the investigator has determined that treatment is not in the best interest of the patient, whichever occurs first.

Conditions

• Breast Cancer
• Metastasis

Interventions

Type	Name	Description
DRUG	Fulvestrant	intramuscular injection 250 mg
DRUG	Tamoxifen	20 mg oral tablet

Timeline

• Start date: 1998-11-01
• Primary completion: 2007-03-01
• Completion: 2012-01-01
• First posted: 2005-10-19
• Last updated: 2012-06-06

Locations

139 sites across 26 countries: United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Mexico, Netherlands, New Zealand, Poland, Portugal, Russia, South Africa, Spain, Taiwan, Turkey (Türkiye), United Kingdom